Big news: We've closed a $24 million Series A funding round, led by Insight Partners.Learn more here!

Condor vs. Auxilius

The Financial Intelligence Layer built for life sciences R&D.

Pharmaceutical companies spend $300 billion annually on R&D — yet the financial infrastructure that determines which programs get funded still runs on spreadsheets. Condor was built to change that.

Unified intelligence

One connected source of truth for R&D finance

Condor's AI-powered technology automatically connects and unifies clinical, operational, and financial data from disparate systems and vendors — giving R&D teams trustworthy data that empowers them to operate with confidence and bring therapies to patients faster and more cost effectively.

AI purpose-built for life sciences

Not a horizontal tool configured for pharma — Condor is architected from the ground up for pipeline economics and the unique forecasting challenges of drug development.

Enterprise-grade. Compliance by design. Audit-ready.

Founded by an EY auditor. Built with the Big 4 to establish clinical trial finance best practices. Every output is traceable, explainable, and defensible — your team owns the numbers.

Trusted by the best in biopharma

Trusted by accounting, FP&A, and clinical operations teams at Menarini Group, Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals. Customers report 90%+ forecast accuracy, 70% faster month-end close, and up to 30% budget savings.

Side-by-side comparison

How Condor and Auxilius compare

For R&D finance teams who need to make high-stakes decisions with confidence, the differences between a purpose-built financial intelligence layer and a managed services workbook are significant.

Positioning

The single source of financial truth for life sciences — unifying R&D pipeline data, clinical activity, and capital allocation into one intelligent system CFOs and boards can trust.

Auxilius

A cloud-based FP&A and accounting workbook for managing clinical trial financial operations.

Primary buyer

CFO, R&D FP&A, and Clinical Ops — financial leadership making portfolio-level decisions.

Auxilius

CFO, Clinical Ops, FP&A — but feedback indicates the tool skews more clinical ops-friendly than CFO-ready.

Customer profile

Enterprise-credible logos: Acadia Pharmaceuticals, BridgeBio Pharma, Madrigal Pharmaceuticals, Alumis Therapeutics.

Auxilius

Customer base skews small and emerging — Fractyl, PMV Pharma, Incendia, Abcuro — with a stated push upmarket.

Foundation & credibility

Founded by an EY auditor; clinical and financial ontologies co-developed with Big 4 firms — a durable, institutional differentiator.

Auxilius

Credibility built on customer volume and faster SMB market entry, not institutional co-development.

Accrual methodology

Protocol-driven cost recognition based on real EDC data — 80% of comparable setups never get properly configured without this foundation.

Auxilius

Operational-driver accruals available but heavily services-dependent — most customers default to CRO estimates instead.

Scope & breadth

Connect/Compass/Copilot suite spans data unification, scenario modeling, and close automation across the entire enterprise.

Auxilius

Laser-focused on R&D accruals and clinical trial financial management — does not cover enterprise-wide financial intelligence.

Integrations

Deep, bidirectional integrations across EDC, CTMS, ERP, and financial systems — data flows in and out automatically.

Auxilius

Ingestion technically possible but the workflow is complex enough that most customers don't set it up themselves.

Ownership model

Your team owns the data, models, and insights — Condor is for organizations ready to control their own financial infrastructure.

Auxilius

Vendor runs the workbook on your behalf — well-suited for teams without internal finance infrastructure, but creates dependency at scale.

Scenario modeling

Condor is the clear leader — real-time, self-serve scenario planning owned by your finance team, not queued through a vendor.

Auxilius

Forecasting limited to future-basis accrual estimates; not intuitive for dynamic portfolio-level modeling.

Audit readiness

Compliance by design — traceable to operational drivers, built for 404b, IPO readiness, and Big 4 audit scrutiny.

Auxilius

SOX/404 controls present, but audit trail relies on the services team's documentation rather than the system itself.

What Condor does

Replace manual reconciliation with real-time financial clarity

Condor automatically unifies clinical, operational, and financial data from disparate systems and vendors. Every capability is designed to move your team from reactive to proactive.

01

Protocol-driven accruals

Expenses recognized based on the clinical protocol schedule and real EDC data — not CRO tracker estimates. Most teams using services-based tools never get operational-driver accruals properly configured and default to CRO estimates instead. Condor makes the right approach the default.

$750K–$1.25M earlier financial insight per program

02

Amendment & change order visibility

Surfaces pending protocol changes and budget amendments before contracts close. Accrue against expected changes to smooth quarter-end spikes and avoid audit questions.

$750K–$1.25M forecast accuracy improvement

03

Automated data reconciliation

SMART Mapping automatically ingests and reconciles data across EDC, CTMS, ERP, and investigator payment systems — eliminating multi-day manual reconciliation cycles every close.

$300K–$500K annual efficiency improvement

04

Scenario planning & forecasting

Condor is the clear leader in dynamic scenario modeling. Model the impact of adding sites, accelerating enrollment, adjusting timelines, or expanding geographies — and answer the CFO's "what if" in the meeting, not two days later by email.

$750K–$1.25M optimization potential per $25M trial

05

Compliance by design

Built on a proprietary clinical and financial data standard co-developed with EY, KPMG & PwC. Every output is traceable, explainable, and defensible — audit-ready by default, not by effort.

Co-developed with EY, KPMG & PwC

06

Total value delivered

Across a typical $25M clinical program, Condor delivers measurable financial impact. Customers report 90%+ forecast accuracy, 70% faster month-end close, and 30% average budget savings.

$2M–$3M per clinical program

R&D Finance Maturity Model

Where does your team stand?

Your trials are growing. Your spreadsheet is not. As your portfolio scales, finance, accounting, and clinical operations cannot stay aligned on a patchwork of manual files. The right solution depends on where you need to be — not just where you are today.

Level 1

Workbook / Spreadsheet

Excel modelsCRO reportsManual calculations$250B in trial spend managed here today

Level 2

Managed services workbook

Vendor-run data ingestionCRO-estimate accrualsInvestigator spend moduleWhite-glove ops team includedBest for teams without internal finance infra

Level 3

Financial intelligence

Finance-owned modelsReal-time scenario planningAudit-ready controlsProtocol-driven accrualsDeep bidirectional integrationsPortfolio-level reportingBig 4 co-developed

Trusted by leading biopharma

Built for CFOs. Trusted by accounting, FP&A, and clinical operations.

Condor manages over $19 billion in R&D spend and is trusted by organizations including Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals.

Accuracy

0

%

+

Forecast accuracy reported by Condor customers

Performance

0

%

Faster month-end close for finance teams on Condor

Savings

0

%

Average budget savings reported by customers

Scale

$

0

B+

In R&D spend managed on Condor today

Frequently Asked Questions about Condor

How is Condor different from other clinical trial finance tools?

The real question is: do you want a vendor running your data, or do you want to control it yourself? Auxilius does a great job as a service for emerging biotechs without internal finance infrastructure. Condor is for organizations that already have that structure, or are building toward it, and are ready to take their financial intelligence to the next level. Your team owns the models, runs scenarios in real time, and can answer the CFO's questions without waiting on a vendor.

What makes Condor trustworthy for audit and compliance purposes?

Condor was founded by a former EY auditor, and its proprietary clinical and financial data standard was co-developed with EY, KPMG, and PwC over years of embedded work with biopharma finance and audit teams. Every output is traceable to its operational driver with transparent calculation logic. That means your team can walk any CFO, audit committee, or Big 4 auditor through your numbers — with or without the vendor in the room.

Does Condor handle the full R&D finance workflow, or just accruals?

Condor's Connect/Compass/Copilot suite covers the full scope: protocol-driven accruals, amendment tracking, automated reconciliation across EDC/CTMS/ERP, real-time scenario modeling, portfolio-level reporting, and audit-ready compliance controls. Condor is particularly differentiated in scenario planning and integrations — with deep bidirectional connections to the systems your team already uses, data flows automatically rather than requiring manual ingestion workflows.

Is Condor right for our stage of growth?

Condor serves both emerging biotechs and top-tier pharma. Scaling teams get white-glove onboarding and dedicated customer success with clinical finance and technical accounting expertise. Enterprise organizations get full automation, portfolio-level forecasting, and managed financial operations. If you are planning for 404b readiness, an IPO, or simply need your CFO to trust the numbers in the board deck — Condor is the infrastructure that makes that possible.

Get in touch

A world where no therapy is delayed by financial uncertainty.See how leading biopharma teams like Acadia, BridgeBio, and Madrigal use Condor to close faster, forecast with confidence, and bring therapies to patients sooner.